Published on 21 Oct 2020:

Meticulous Research®– leading global market research company published a research report titled Urinalysis Market by Product (Pregnancy & Fertility Test, Dipstick, Reagent, Automatic, Semi-automatic, and POC Analyzer), Application (Pregnancy, Diabetes, Kidney Disease, UTI), End-user (Hospitals and Clinics, Laboratory, Home Care) - Forecast to 2027”.

According to this latest publication from Meticulous Research®, the urinalysis market is expected to grow at a CAGR of 4.5% from 2019 to 2027 to reach $2.19 billion by 2027. The growth of the urinalysis market is mainly attributed to the rising prevalence of kidney diseases and urinary tract infections, growing regular health checkups by geriatric population, and introduction of technologically advanced diagnostic products. However, the ambiguity in the regulatory framework is the key factor expected to hinder the adoption of urinalysis products to a certain extent.

Impact of COVID-19 on the Urinalysis Market

The COVID-19 global pandemic is affecting people in various ways. In recent studies on COVID-19 patients, an influence on kidney function was also found in certain patient groups, including those with acute kidney damage and proteinuria. Acute kidney injury (AKI) has been reported in up to 25% of critically ill patients with the SARS-CoV-2 infection, especially in those with underlying comorbidities. As the pandemic is still in its active phase, and many symptoms have not yet been fully described, careful clinical observation is important, and wherein urinalysis can be a useful tool. Viruses are usually detected in urine in various ways, including the detection of inclusion bodies in the urinary sediment cells using sediment analyzers. Microscopic examination of the urinary sediment is a reliable clinical tool of diagnostic and prognostic value in AKI assessment. Also, the urine samples of COVID-19 patients on biochemical parameters will help determine kidney functioning.

During COVID-19 treatment, experts noticed that the kidneys, in addition to the lungs and heart, are also affected at an early stage, especially in the most seriously ill patients. Urine analysis showed that significant abnormalities were already observed days before a rapid worsening of the COVID-19 infection. In addition to the urine findings, albumin in urine was used to diagnose the capillary leak syndrome, predicting fluid overload and respiratory failure. Patients who developed a severe course of COVID-19 exhibited albumin and leukocytes in urine. It has been suggested that cases of CoV-AKI may exhibit a high frequency of proteinuria, hematuria, and leukocyturia. The recently published IFFC Guide on COVID-19 suggests testing for albumin in patients with COVID-19. Low albumin levels have been reported in patients with severe forms of the disease, and hypoalbuminemia was associated with mortality in hospitalized patients. Hence, urine biochemical parameters are also helpful in evaluating the changes in patients with COVID-19.

Urinalysis Market: Future Outlook

The urinalysis market study presents historical market data in terms of values (2018 and 2019), estimated current data (2020), and forecasts for 2027- The urinalysis market study includes the market analysis by product [consumables (pregnancy & fertility tests, dipstick, and other consumables), instruments (automated urine analyzers, biochemical urine analyzers, sediment urine analyzers, semi-automated urine analyzers, integrated urine analyzers, and point-of-care analyzers)], application [urine tract infections, kidney diseases, diabetes, and other diseases; and pregnancy & fertility testing], end user [hospitals and clinics, diagnostic laboratories, home care settings, and research laboratories and institutes] and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.

On the basis of product, the market is broadly segmented into consumables and instruments. The instruments segment is further categorized into automated urine analyzers and point-of-care analyzers. In the instruments market, automated urine analyzers are estimated to account for the largest share in 2020. The high adaptation rate of upgraded and advanced systems, which provide high productivity and are easy to use, is one of the major factors driving the growth of this segment.

On the basis of application, the disease screening segment is estimated to hold the largest share of the overall urinalysis market in 2020. Further, the UTI segment under disease screening is estimated to hold the largest share owing to growing incidences of urinary tract infections globally and widespread awareness regarding UTI treatments and diagnosis.

Based on the end user, in 2020, the hospitals & clinics segment is estimated to account for the largest share of the overall urinalysis market. The growing number of people visiting hospitals and clinics for general health checkups and improvement in hospital infrastructure and associated instruments are some of the key factors driving the growth of the urinalysis market for this end-user segment.

This research report analyzes major geographies and provides a comprehensive analysis for North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America, and the Middle East & Africa. North America is estimated to dominate the overall urinalysis market in 2020, followed by Europe and Asia-Pacific. The growing prevalence of chronic diseases associated with the geriatric population, high awareness regarding general periodic health checkups among people, continuous new product launches by key players, growing installation of automated devices in large hospitals & diagnostic laboratories, and easy access to advanced products accelerate the growth of the urinalysis market in North America.

The key players operating in the urinalysis market are Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), Siemens Healthineers (Germany), Sysmex Corporation (Japan), ARKRAY, Inc (Japan), ACON Laboratories, Inc. (U.S.), Cardinal Health, Inc. (U.S.), URIT Medical Electronic Group Co., Ltd. (China), and 77 Elektronika Kft. (Hungary).

Download Free Sample Report @

Contact Us:
Meticulous Research®
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn-

Download Free Sample